Abstract
The scaffold protein Axin plays important roles in multiple signaling pathways through mediating the formation of different signaling complexes. Axin is best known for its role as a negative regulator in Wnt/β-catenin pathway. Aberrant activation of the key components in Wnt/β-catenin pathway including Axin has been linked to a variety of human cancers. Drugs developed for this pathway are far from satisfying largely due to the limited targets especially enzymesin this pathway. Almost all Axinsignal pathways depend on a number of protein-protein interactions (PPIs) for transmitting information, making PPIs attractive targets and probably a future direction for drug discovery. Axin interacts with a plethora of proteins, positively or negatively regulating several signaling pathways that are closely involved in the pathogenesis of human disease. Studies in recent years indicated Axin as a promising target for treating Wnt-driven diseases. With the identification of more interacting partners for Axin and increased understanding about the roles of these Axin-mediated PPIs in human disease, new targets may surface from the Axin PPI networks, which may lead to the generation of new drugs and treatmentstrategies. In this review, we outline the Axin PPI networks in several pathways especially in Wnt signaling and discuss how those Axin-interacting proteins affect the respective signaling pathways through an interaction with Axin.
Keywords: Axin, Signaling pathways, Protein-protein interactions, Drug target, Wnt/β-catenin pathway.
Current Topics in Medicinal Chemistry
Title:Axin PPI Networks: New Interacting Proteins and New Targets?
Volume: 16 Issue: 30
Author(s): Xiaomin Song, Wenwen Cai and Lin Li
Affiliation:
Keywords: Axin, Signaling pathways, Protein-protein interactions, Drug target, Wnt/β-catenin pathway.
Abstract: The scaffold protein Axin plays important roles in multiple signaling pathways through mediating the formation of different signaling complexes. Axin is best known for its role as a negative regulator in Wnt/β-catenin pathway. Aberrant activation of the key components in Wnt/β-catenin pathway including Axin has been linked to a variety of human cancers. Drugs developed for this pathway are far from satisfying largely due to the limited targets especially enzymesin this pathway. Almost all Axinsignal pathways depend on a number of protein-protein interactions (PPIs) for transmitting information, making PPIs attractive targets and probably a future direction for drug discovery. Axin interacts with a plethora of proteins, positively or negatively regulating several signaling pathways that are closely involved in the pathogenesis of human disease. Studies in recent years indicated Axin as a promising target for treating Wnt-driven diseases. With the identification of more interacting partners for Axin and increased understanding about the roles of these Axin-mediated PPIs in human disease, new targets may surface from the Axin PPI networks, which may lead to the generation of new drugs and treatmentstrategies. In this review, we outline the Axin PPI networks in several pathways especially in Wnt signaling and discuss how those Axin-interacting proteins affect the respective signaling pathways through an interaction with Axin.
Export Options
About this article
Cite this article as:
Song Xiaomin, Cai Wenwen and Li Lin, Axin PPI Networks: New Interacting Proteins and New Targets?, Current Topics in Medicinal Chemistry 2016; 16 (30) . https://dx.doi.org/10.2174/1568026616666160622220245
DOI https://dx.doi.org/10.2174/1568026616666160622220245 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Thymoquinone Anticancer Discovery: Possible Mechanisms
Current Drug Discovery Technologies Therapeutic Use of Molecules that Mimic Pathogen Danger Signals
Endocrine, Metabolic & Immune Disorders - Drug Targets Translational Gap in Glioma Research
Anti-Cancer Agents in Medicinal Chemistry Cytotoxic Properties of Clofibrate and other Peroxisome Proliferators: Relevance to Cancer Progression
Current Medicinal Chemistry MiR-125b Inhibits Cell Proliferation and Induces Apoptosis in Human Colon Cancer SW480 Cells <i>via</i> Targeting STAT3
Recent Patents on Anti-Cancer Drug Discovery Stem Cell Transplantation and MBL Replacement Therapy
Current Stem Cell Research & Therapy Heat Shock Protein 90 Inhibitors in Oncology
Current Proteomics Phytochemicals and Cancer Stem Cells: A Pancreatic Cancer Overview
Current Chemical Biology Base-Modified Nucleosides as Chemotherapeutic Agents: Past and Future
Current Topics in Medicinal Chemistry The Link Between CD6 and Autoimmunity: Genetic and Cellular Associations
Current Drug Targets Liposomal-All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
Current Cancer Therapy Reviews Aptamer-Mediated Cancer Gene Therapy
Current Gene Therapy Phosphonomethoxyalkyl Analogs of Nucleotides
Current Pharmaceutical Design MicroRNAs as Cancer Biomarkers
MicroRNA Tubulin Inhibitors: A Patent Survey
Recent Patents on Anti-Cancer Drug Discovery Revisiting Non-Cancer Drugs for Cancer Therapy
Current Topics in Medicinal Chemistry Immunotherapeutic Options for Pediatric Malignancies
Current Immunology Reviews (Discontinued) Gene Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Quantitative Structure-Activity Relationship Studies: Understanding the Mechanism of Tyrosine Kinase Inhibition
Current Enzyme Inhibition On the Origin of Epidermal Cancers
Current Molecular Medicine